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ABSTRACT
Prostate cancer is the most common type of non-skin malignancy diagnosed among men,
but the disease etiology and risk factors remain inconclusive. Hepatitis C virus (HCV)
infection’s prevalence is increasing in the US population. Studies have shown that the
concentration of free serum testosterone, which may be directly associated with prostate
cancer risk, was decreased among men with HCV infection. In order to evaluate the
relationship between HCV infection and prostate cancer risk, we conducted a populationbased case-control study using the SEER-Medicare dataset.
The study included 194,339 prostate cancer cases and 54,481 controls which were
frequency-matched to the cases by age, race, and calendar period of selection. After
adjusting for matching factors and potential confounders, including geographic region of
SEER registry/area, HBV infection, HIV infection, hypertension, number of
hospitalization, number of outpatient visits, number of physician visits, and PSA test 00.99 years prior to index date, history of HCV infection was significantly associated with
decreased risk of prostate cancer (OR 0.76, 95% CI: 0.63-0.93). In addition, with the
controls as the reference group, we observed HCV infection to be associated with
reduced prostate cancer risk within each prostate cancer stage category at diagnosis:
localized (OR 0.86, 95% CI: 0.59-1.24), regional (OR 0.90, 95% CI: 0.43-1.89), distant
(OR 0.56, 95% CI: 0.26-1.17), and unstaged (OR 0.62, 95% CI: 0.38-1.00).
Our finding that HCV infection is associated with reduced prostate cancer risk may lead
to a greater understanding of prostate cancer etiology. Future research will be needed to
elucidate the underlying biological mechanism for this inverse association.
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INTRODUCTION
Prostate cancer is the most common type of non-skin malignancy diagnosed among men,
and the American Cancer Society has projected that about 238,590 new cases of prostate
cancer will be diagnosed in the United States during 2013. Despite the high disease
burden and wide-scope of research on prostate cancer etiology, the established risk
factors of prostate cancer only include older age, a positive family history, and AfricanAmerican race (Hoffman, 2011; Dunn et al. 2011; Johns 2003). Interestingly, certain
conditions, including diabetes mellitus (Kasper et al. 2006; Bonovas et al. 2004) and
Human Immunodeficiency Virus (HIV) infection (Patel et al. 2008), seem to be
associated with decreased risk of prostate cancer.
Prostate cancer is rarely diagnosed clinically among men less than 40 years of age. The
serum prostate-specific antigen (PSA) test has been widely adopted as a screening test for
prostate cancer since the late 1980s (Lin et al. 2008), but the efficacy of the test has been
controversial, as it has not been demonstrated to decrease mortality but induce harms
such as over-diagnosis and over-treatment (Chou et al. 2011). PSA test diagnosed
prostate cancer is usually asymptomatic and localized, compared to clinically detected
prostate cancer, which is more likely to be diagnosed with regional extension or
metastases (Hoffman et al. 2005). In 2011, the U.S. Preventive Services Task Force
(USPSTF) recommended against screening for prostate cancer among all American men,
regardless of age, race/ethnicity, or family history, as the current evidence indicates that
the benefits of the test do not outweigh the harms (Moyer, 2012).
It is estimated that approximately 2% (5.2 million) of the U.S. population is infected with
hepatitis C virus (HCV) (Chak et al. 2011). HCV infection is an established strong risk
factor for development of subsequent liver cirrhosis (Perz et al. 2006), hepatocellular
carcinoma (HCC) (El-Serag 2000; Amin et al. 2006), and other liver complications
(Hoofnagle 1997). Emerging evidence has also suggested a carcinogenic role of HCV
infection in other types of cancer, including: non-Hodgkin lymphoma (NHL) (Matsuo et
al. 2004; Giordano et al. 2007), thyroid cancer (Antonelli et al. 2007; Montella et al.
2003), pancreatic cancer (El-Serag et al. 2009), and intrahepatic cholangiocarcinoma
(Yamamoto et al. 2004). HCV-induced chronic liver inflammation causes accumulation
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of reactive oxygen intermediates, which creates a mutagenic environment that inhibits
DNA repair and allows the mutated cells to proliferate (Colombo 2003). This has been
suggested to increase the risk of HCC. The increased NHL risk seen after HCV infection
may be due to HCV-induced immune disturbance and B-cell proliferation (Negri et al.
2004; Gasparotto et al. 2002). There is also evidence that HCV core protein promotes cell
proliferation and inhibits apoptosis(Chen et al. 2005), as a possible mechanism of HCV
carcinogenesis.
Extrahepatic manifestations of chronic HCV infection have been reported to include
altered seminal parameters and reduced spermatogenesis (Hofny et al. 2011). Compared
to healthy controls, HCV infected men are observed to have reduced semen volume and
sperm motility (Hofny et al. 2011), and significantly lower free serum testosterone
concentration (Durazzo et al. 2006). The latter may be explained by increased excretion
of sex hormone-binding globulin after HCV infection (Nguyen et al. 2005). Testosterone
is an androgen essential for proper function of the prostate gland, and previous research
has suggested that higher serum testosterone levels are associated with increased risk of
developing prostate cancer (Parsons et al. 2005). Therefore, it is possible that HCVinfected men may have diminished risk of prostate cancer because of the decreased
concentration of circulating testosterone.
To our knowledge, no published study has examined the relationship between HCV
infection and prostate cancer risk. In order to fill this research gap, we have conducted a
population-based case-control study using the Surveillance, Epidemiology and End
Results (SEER)-Medicare linked database. Besides assessment of the exposure variable,
this database also provides information about several other variables, including
demographic features, medical history, healthcare utilization, and PSA testing history.
The availability of these variables allowed us to adjust for potential confounders and
obtain a more accurate estimate of prostate cancer risk among HCV-infected patients.
Our research may lead to a greater understanding of prostate cancer etiology.
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METHODS
SEER-Medicare dataset
The SEER program is funded by National Cancer Institute, and it collects data on cancer
incidence and survival from US cancer registries. Presently, SEER includes 17 cancer
registries, which covers approximately 26% of the US population. Medicare is a federally
funded program which provides health insurance for approximately 97% of people aged
65 years or older in the US population, as well as individuals under age 65 who have endstage renal disease or medical disability. Medicare is composed of four parts, including
inpatient hospitalization program (Part A), physician visits and outpatient service
program (Part B), Medicare Advantage plan (Part C) where benefits are provided by
private companies that contract with Medicare, and outpatient prescription drug benefit
(Part D).
The SEER-Medicare is a linked database that provides demographic and clinical
information for all incident cancers in the SEER program, as well as claims data for the
individuals that are covered under Medicare and living in SEER regions (Engels et al.
2011). Medicare data are available for both the cancer cases identified in the SEER
program, and a 5% random sample of the Medicare population from the same geographic
regions. Medicare data includes claims information for inpatient and hospitalization
service (since 1986), and physician and outpatient services (since 1991). The claims are
coded using International Classification of Diseases (ICD-9) codes, and Current
Procedures Terminology (CPT-4) codes.
Study design and subject selection
In order to examine the risk of prostate cancer among HCV-infected individuals, we
conducted a population-based case-control study using the SEER-Medicare dataset. Since
almost all American people enter the Medicare program once their age reaches the
eligibility criteria, Medicare can be considered as a cohort of the US general population
65 years of age or older.
This study was part of a larger project in which we systematically identified 1,084,247
first primary cancer cases of any type diagnosed during 1993-2005 and aged 66 or older
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at the time of diagnosis. We excluded persons of age 65 to assure sufficient time for the
ascertainment of exposure information. Individuals who were diagnosed with cancer
before 1993 were also excluded, since the Medicare system does not have claims data for
HCV infection prior to 1993. The cases were required to have at least 12 month nonhealth maintenance organization (HMO), Part A, and Part B Medicare claims data prior
to the diagnosis of first cancer, in order to assure completeness of data and sufficient time
to evaluate HCV infection status before cancer diagnosis. Cases diagnosed on autopsy or
by death certificates only were excluded. The date of diagnosis was assigned as the index
date for the cases.
A total of 100,000 controls were randomly selected from the 5% random sample of
Medicare recipients. Controls were frequency matched to the all-cancer cases by calendar
year of case diagnosis, age, sex, and race. We required that controls be alive, and with no
SEER-reported cancer on or before July 1st in the calendar year of selection. The same
control could be selected multiple times for cases in different calendar years, and could
become a cancer case in the future. The index date of the controls was July 1st of the
selection year. Like cases, we required controls to have at least 12 months of non-HMO,
Part A, and Part B Medicare coverage prior to their index dates.
To conduct the current study, we extracted all first prostate cancer cases (194,339) and all
male controls (54,481) into a sub-dataset, and used this sub-dataset to investigate the
association between HCV infection and prostate cancer risk. This study can be
conceptualized as a nested-case control study in the cohort of the US Medicare elderly
population.
Ascertainment of HCV infection status and covariates
HCV infection status for the selected cases and controls was determined using the
Medicare claims data. Subjects with one or more inpatient, hospital-based outpatient, or
physician claims for HCV infection (ICD 9 codes: 070.41, 070.44, 070.51, 070.54,
070.70, 070.71, or V02.62) were classified as having HCV infection. It is possible that
the cancer patients received more diagnostic tests, including laboratory tests for HCV,
during the period preceding their diagnosis than did controls during the period preceding
their index date. As a result, cases are more likely to detect their asymptomatic hepatitis
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viral infection than controls. Therefore, we excluded the HCV infections diagnosed
within the 12-month period before cancer diagnosis or index date for both cases and
controls, so as to avoid information bias.
We collected information regarding other pertinent medical conditions for each selected
individual, using the Medicare claims data for inpatient, hospital-based outpatient, or
physician care. These conditions include diabetes mellitus (ICD 9 code: 250.0x), hepatitis
B virus infection (HBV, 070.2, 070.3), hypertension (401.x-405.x), and HIV infection
(042-044). We ascertained patients’ numbers of hospitalizations, hospital-based
outpatient visits, and physician visits between age 65 and their index date, since we
believe the utilization pattern of healthcare service may be associated with the likelihood
of being diagnosed with prostate cancer or HCV infection. We expect that patients with
HCV infection or chronic medical conditions would receive more healthcare services,
including PSA screening tests, which increases the likelihood of diagnosis of early-stage
prostate cancer. For the patients who had screening-detected cancer, their PSA tests were
most probably done within a short period prior to their cancer diagnosis. As a result, we
also assessed whether each subject had received PSA test 0-0.99 years prior to the index
date, in order to adjust for the potential confounding caused by PSA screening.
Statistical analysis
We computed descriptive statistics of demographic characteristics, medical conditions,
and healthcare utilization, for both prostate cancer cases and controls. We assessed
whether these covariates were significantly associated with the primary exposure variable
and the cancer outcome.
We conducted stratified analyses by each covariate and examined whether the odds ratio
(OR) for prostate cancer comparing HCV-infected to uninfected subjects was
heterogeneous across levels of the covariates. For the continuous variables of healthcare
utilization, we divided the variables at the median among the controls, and created new
binary variables that represent the number of people who have more or less than or equal
to the median numbers of visits to healthcare facilities. If no heterogeneity was found
with assessment of the Breslow-Day test p-value, we used the Mantel-Haenzsel summary
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OR to represent the risk of prostate cancer after HCV infection for each stratified
analysis.
To compare prostate cancer risk between HCV-infected and non-infected subjects, we
used an unconditional logistic regression model to compute ORs and 95% confidence
intervals (95% CIs), with adjustment for the matching factors and other potential
confounders. The covariates included in the model were age, race, calendar period of
selection (1993-1995, 1996-2000, 2001-2005), geographic region of SEER registry/area,
HBV infection, HIV infection, hypertension, number of hospitalizations, number of
hospital-based outpatient visits, number of physician visits, and whether the individual
had received a PSA test 0-0.99 years prior to the index date. A body of research has
suggested that HCV infection leads to elevated risk of developing diabetes mellitus (Noto
et al. 2006), and that the latter is associated with decreased the risk of prostate cancer, as
mentioned previously. We therefore excluded diabetes from our model, since it may be in
the causal pathway between HCV infection and prostate cancer risk.
We suspected that having a PSA test 0-0.99 years prior to the index date may also be an
effect modifier of the association between HCV infection and prostate cancer risk, so we
included an interaction term between our primary predictor, HCV infection, and our PSA
test variable in the above unconditional logistic regression model. If this interaction term
was found to be statistically significant, it would suggest that the effect of HCV infection
on prostate cancer risk differs according to whether the patient has received a PSA test 00.99 years prior to their index date. As a result we would also report stratum-specific ORs
according to PSA test status.
In order to explore the association between HCV infection and prostate cancer risk
stratified by stage at diagnosis, cases were divided into four cancer-stage categories:
localized (stage I and II by the TNM system), regional (stage III by the TNM system),
distant (stage IV by the TNM system), and unstaged. Using polytomous logistic
regression, we calculated ORs for HCV-infected versus HCV uninfected subjects for
each cancer stage category compared to controls, and assessed whether the ORs were
heterogeneous. The interaction term between HCV infection and the PSA test variable
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was also included in the above polytomous logistic regression models, in order to detect
effect modification from PSA screening.
To adjust for the multiple selection of a control across calendar years, and the possibility
that a control can become a case in the future, the variance of the ORs from all logistic
regression models were adjusted (Engels et al. 2011).

RESULTS
The study included 194,339 men with the diagnosis of first primary prostate cancer, and
54,481 male controls (Table 1). Because of the large sample size, even a slight numerical
difference between cases and controls can be statistically significant, but not necessarily
meaningful. The mean ages of cases and controls were similar, 74.73 ± 6.14 years and
75.17 ± 6.68 years, respectively. More than 80% of the subjects were white in both
groups, but there were relatively more black subjects in the control group than in the case
group (10.58% versus 6.43%, respectively). Among the cancer cases, 46% of the subjects
were selected during 2001-2005, and approximately 25% were selected during 19931995 and 1996-2000, respectively. The distribution of calendar period of selection is
slightly different in the control group. Overall, the cases and controls were fairly wellmatched on age, race, and calendar period of selection from numerical comparison,
despite the statistically significant difference.
Table 1. Characteristics of cancer cases and controlsa
Characteristic

Prostate cancer
Yes (N = 194,339)b No (N = 54,481)b

HCV
Yes
no
Age (years)
Race
White
Black
Others
Calendar-period of selection
1993-1995
1996-2000
2001-2005

	
  

469 (0.2%)
193,870 (99.8%)
74.7 ± 6.1

174 (0.3%)
54,307 (99.7%)
75.2 ± 6.7

45,747 (84.1%)
3,497 (6.4%)
5,124 (9.4%)

161,001 (83.0%)
20,524 (10.6%)
12,442 (6.4%)

49,918 (25.7%)
54,370 (28.0%)
90,051 (46.3%)

11,048 (20.3%)
16,277 (29.9%)
27,156 (49.8%)
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< 0.001*

< 0.001*
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History of diabetes
Yes
29,729 (15.3%)
No
164,612 (84.7%)
History of HBV
Yes
212 (0.1%)
No
194,127 (99.9%)
History of hypertension
Yes
80,769 (41.6%)
No
113,570 (58.4%)
History of HIV
Yes
302 (0.2%)
no
194,037 (99.8%)
PSA test 0-0.99 years prior to the index date
Yes
132,048 (68.0%)
no
62,291 (32.1%)
# of hospitalizations
1.5 ± 2.4
# of outpatient visit
11.7 ± 17.5
# of physician visit
98.2 ± 100.8

Yale School of Public Health

< 0.001*
9,780 (18.0%)
44,701 (82.1%)
88 (0.2%)
54,393 (99.8%)
23,719 (43.5%)
30,762 (56.5%)
94 (0.2%)
54,387 (99.8%)
19,341 (35.5%)
35,140 (64.5%)
1.6 ± 2.8
11.5 ± 19.7
96.7 ± 112.2

0.0018*
< 0.001*
0.3751*
< 0.001*

< 0.001***
< 0.001***
< 0.001***

Table values are mean ± SD for continuous variables and n (column %) for categorical variables.
Percentages may not sum to 100% due to rounding.
*
P-value for χ2 test. ** P-value for t-test. ***P-value for Non-parametric test.
b

In our dataset, 469 (0.24%) cases and 174 (0.32%) controls had a history of HCV
infection. These proportions are substantially lower than the estimated prevalence of
HCV infection (1.6%) in the US general population (Armstrong et al. 2006), but
consistent with the percentage reported by Anderson et al. (2008) using analogous SEERMedicare data. Approximately 18.0% of subjects in the control group had a history of
diabetes, compared to 15.3% in the case group. Less than 0.2% of cases and controls,
respectively, had a history of HBV infection; the proportion of subjects with HIV
infection was equally small in both groups. Hypertension was diagnosed in 41.6% of
cases, which was slightly lower than the percentage of controls with hypertension. In
addition, 68.0% of cases received a PSA test 0-0.99 year prior to their index dates,
compared to 35.5% of the controls. Among the cases, 83.0% of HCV-infected men
received a PSA test 0-0.99 years prior to their index date, compared to 67.9% among the
HCV un-infected men.
On average, the prostate cancer cases and controls were hospitalized 1.5 and 1.6 times,
respectively, between age of 65 and the year of selection. The mean numbers of
outpatient visits and physician visits were similar between cases and controls (about 12
outpatient visits and 97 physician visits).
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Table 2. Characteristics of HCV infected and uninfected subjectsa

a

HCV infection
Characteristic
Yes (N = 643)b
No (N = 248,177)b
Age (years)
74.0 ± 5.2
74.8 ± 6.3
Race
White
461 (71.8%)
206,287 (83.3%)
Black
111 (17.3%)
23,910 (9.7%)
Others
70 (10.9%)
17,496 (7.1%)
Calendar-period of selection
1993-1995
9 (1.4%)
60,957 (24.6%)
1996-2000
110 (17.1%)
70,537 (28.4%)
2001-2005
524 (81.5%)
116,683 (47.0%)
Diabetes
Yes
194 (30.2%)
39,313 (15.8%)
No
449 (69.8%)
208,864 (84.2%)
Hepatitis B
Yes
55 (8.6%)
245 (0.1%)
No
588 (91.5%)
247,932 (99.9%)
Hypertension
Yes
411 (63.9%)
104,077 (41.9%)
No
232 (36.1%)
144,100 (58.1%)
HIV
Yes
19 (3.0%)
377 (0.2%)
no
624 (97.1%)
247,800 (99.9%)
PSA test 0-0.99 years prior to the index date
Yes
472 (73.4%)
150,917 (60.8%)
no
171 (26.6%)
97,260 (39.2%)
Num of hospitalizations
2.9 ± 4.4
1.5 ± 2.5
Num of outpatient visit
26.1 ± 34.0
11.6 ± 18.0
Num of physician visit
205.6 ± 199.7
97.6 ± 102.9

p
< 0.001**
< 0.001*

< 0.001*

< 0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

< 0.001***
< 0.001***
< 0.001***

Table values are mean ± SD for continuous variables and n (column %) for categorical variables.
Percentages may not sum to 100% due to rounding.
*
P-value for χ2 test. ** P-value for t-test. ***P-value for Non-parametric test.
b

Table 2 compares the characteristics of the HCV infected and uninfected subjects. Their
mean ages were similar. Among the HCV-infected subjects, 71.8% were white and
17.3% were black, compared to 83.3% and 9.7%, respectively, for the uninfected
subjects. More than 80% of the HCV-infected subjects, but only 47.0% of the HCVuninfected subjects, were selected during 2001-2005. For every medical condition,
including diabetes, hepatitis B infection, hypertension, and HIV infection, the proportion
of subjects having the condition was significantly and substantially greater among HCVinfected subjects than among uninfected subjects. On average, the numbers of
hospitalizations, outpatient visits and physician visits were approximately two times
higher among HCV-infected subjects than among uninfected ones. Of note, 73.4% of
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HCV-infected subjects received a PSA test 0-0.99 years prior to their index date,
compared to approximately 60% among the uninfected subjects.
Table 3. Stratified analysis by categorical covariates
HCV
infection

Prostate cancer
Yes
No

Race
Yes
331
1300
White
No
(N = 206,748)
160,67
45,617
Yes
93
18
Black
(N = 24,021)
No
20,431
3,479
Yes
44
26
Others
no
(N = 17,566)
12,398
5,098
Calendar-period of selection
Yes
7
2
1993-1995
(N = 60,966)
No
49,911
11,046
Yes
77
33
1996-2000
No
(N = 70,647)
54,293
16,244
Yes
385
139
2001-2005
(N = 117,207)
no
89,666
27,017
Diabetes
Yes
136
58
Yes
No
(N = 209,313)
29,591
9,722
Yes
333
116
No
(N = 39,507)
no
164,279
44,585
Hepatitis B
Yes
39
16
Yes
No
(N = 300)
173
72
Yes
430
158
No
(N = 248,520)
no
193,697
54,235
Hypertension
Yes
301
110
Yes
No
(N = 104,488)
80,468
23,609
Yes
168
64
No
(N = 144,332)
no
113,402
30,698
HIV
Yes
12
7
Yes
No
(N = 396)
290
87
Yes
457
167
No
(N = 248,424)
no
193,580
54,220
PSA test 0-0.99 years prior to the index date
Yes
389
83
Yes
No
(N = 151,389)
131,659
19,258
Yes
80
91
No
(N = 97,431)
no
62,211
35,049
# of hospitalizations (median = 0)
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Mantel-Haenzsel OR
(95% CI)
0.74 (0.62, 0.88)

Breslow-Day
test p-value
0.7557

0.81 (0.68, 0.96)

0.7399

0.78 (0.65, 0.92)

0.9530

0.78 (0.65, 0.93)

0.4010

0.77 (0.65, 0.91)

0.5084

0.76 (0.64, 0.90)

0.6453

0.60 (0.50, 0.72)

0.0956

0.73 (0.62, 0.87)

0.1256
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Yes
324
> median
No
(N = 130,359)
103,256
Yes
145
<= median
(N = 118,461)
no
90,614
# of outpatient visits (median = 5)
Yes
356
> median
No
(N = 127,598)
101,746
Yes
113
<= median
(N = 121,222)
no
92,124
# of physician visits (median = 61)
Yes
402
> median
No
(N = 130,678)
103,098
Yes
67
<= median
(N = 118,142)
no
90,772

Yale School of Public Health

125
26,654
49
27,653
0.71 (0.60, 0.85)

0.0147

0.72 (0.61, 0.86)

0.3000

141
25,355
33
28,952
140
27,038
34
27,269

We conducted stratified analyses by each covariate and examined whether the OR for
prostate cancer comparing HCV-infected to uninfected subjects was heterogeneous
across levels of the covariates. Except for number of outpatient visits, the association
between HCV infection and prostate cancer risk was not statistically different across
categories of any covariates (Table 3). Thus, it is reasonable to use the Mantel-Haenzsel
summary OR to represent the risk of prostate cancer after HCV infection for each
stratified analysis except for number of outpatient visits. For all stratified analyses, the
Mantel-Haenszel summary ORs were within the range of 0.60-0.81 and statistically
significant, indicating that the risk of developing prostate cancer was lower among the
HCV-infected compared to HCV-uninfected subjects after controlling for each covariate.
Table 4. Association between HCV infection and prostate cancer riska,b

a.

Prostate cancer
Cancer
No cancer

Number
194,339
54,481

Odds Ratio (95% CI)
0.76 (0.63, 0.93)b
1.00

The reference group is HCV-uninfected subjects.
Adjusted for age, race, calendar-period of selection, geographic region of SEER registry/selection, HBV infection,
HIV infection, hypertension, number of hospitalization, number of outpatient visits, number of physician visits, and
PSA test 0-0.99 year prior to index date.
b.

With adjustment for matching factors and potential confounders, the interaction term
between HCV infection and PSA test was not statistically significant (p=0.58), indicating
that PSA test was not an effect modifier of this association, therefore our final model did
not include interaction term. In the adjusted analysis, history of HCV infection was
significantly associated with decreased risk of prostate cancer (OR 0.76, 95% CI: 0.63-
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0.93) (Table 4). In other words, the risk of developing prostate cancer is suggested to
decrease by approximately 25% after HCV infection. Including diabetes mellitus in the
model did not alter the OR substantially, suggesting that minimal proportion of HCV
infection’s protective effect for prostate cancer is attributed to diabetes.
Table 5. Association between HCV infection and stage at diagnosis of prostate cancera,b

a.

Stage
Controls
Localized
Regional
Distant
Unstaged

Number
54,481
94,894
14,406
15,608
69,431

Odds Ratio (95% CI)
1.00
0.86 (0.59, 1.24)
0.90 (0.43, 1.89)
0.56 (0.26, 1.17)
0.62 (0.38, 1.00)

Localized
Regional
Distant
Unstaged

94,894
14,406
15,608
69,431

1.00
1.09 (0.71, 1.68)
0.64 (0.42, 0.99)
0.72 (0.58, 0.90)

The reference group is people without HCV infection.
Adjusted for age, race, calendar period of selection, geographic region of SEER registry/selection, HBV infection,
HIV infection, hypertension, number of hospitalization, number of outpatient visits, number of physician visits, and
history of PSA test 0-0.99 year prior to index date.
b.

In the polytomous logistic regression model with the controls as the reference group, we
observed HCV infection to be associated with reduced prostate cancer risk within each
prostate cancer stage category at diagnosis: localized (OR 0.86, 95% CI: 0.59-1.24),
regional (OR 0.90, 95% CI: 0.43-1.89), distant (OR 0.56, 95% CI: 0.26-1.17), and
unstaged (OR 0.62, 95% CI: 0.38-1.00) (Table 5). The strongest association was
observed for the most advanced stage of prostate cancer. However, none of these
associations were statistically significant, possibly due to limited power. The ORs were
not heterogeneous from each other (p=0.88). The interaction term between HCV
infection and PSA test was found not statistically significant (p=0.26), suggesting no
effect modification from screening.
When restricting our analysis to only cancer cases with localized cases as the reference
group, we observed a weak, non-significant positive association between HCV infection
and regional prostate cancer (OR 1.09, 95% CI: 0.71-1.68), but a negative and significant
association between HCV infection and distant prostate cancer (OR 0.64, 95% CI: 0.420.99) (Table 5). Again, the ORs were not heterogeneous from each other (p=0.27), and
the interaction terms between HCV infection and PSA test was not significant (p=0.31).
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DISCUSSION
In this population-based case-control study, we have discovered that HCV infection was
associated with reduced prostate cancer risk, after adjusting for demographic features,
relevant medical conditions, numbers of visits to healthcare facilities, and PSA test
history 0-0.99 years prior to the index date. In addition, our results suggested that this
negative association was stronger for late stage prostate cancer than for earlier stage
prostate cancer.
Acute HCV infection is rarely discovered in clinical practice, and patients usually carry
the virus for several years until non-specific symptoms such as fatigue appear. Duzarro et
al. (2006) and Hofny et al. (2011) both reported that HCV-infected patients showed
significantly lower levels of free testosterone compared to healthy controls. Nguyen et al.
(2006) found that free testosterone concentration was inversely correlated with the
severity of liver disease, and the concentration of sex hormone-binding globulin (SHBG)
was higher among patients with more severe liver conditions. Two possible biological
mechanisms have been proposed to explain the observed low level of free testosterone
after HCV infection. One theory is that HCV infection causes primary hypogonadism
(Danoff et al. 2006), under which condition, the functionalities of testicles are
compromised and thus less testosterone is produced. Secondly, the chronic inflammation
at the liver after HCV infection elevates the level of estrogen production (Shimizu et al.
2001; Martino et al. 2004), and more SHBG are produced through the metabolism of
estrogen. With increased the availability of testosterone-binding sites on SHBG, the
concentration of free testosterone circulating in the system is decreased. High
testosterone level has been linked with increased prostate cancer risk (Parsons et al.
2005). The resulting lower level of circulating testosterone level may provide a plausible
biological explanation for the observed diminishing prostate cancer risk among HCVinfected subjects in our study.
In the meta-analysis published by Kasper et al. (2006), the authors observed a significant
inverse association between diabetes mellitus and risk of prostate cancer (RR=0.84, 95%
CI: 0.76-0.93). The underlying mechanism was suggested to involve decreased
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concentration of two hormones: insulin and testosterone. Patel et al. (2008) reported that
the incidence of prostate cancer was significantly lower among HIV-infected individuals
than the general US population (SIR=0.6, 95% CI 0.4-0.8), and HIV infection is known
to decreased androgen levels (Engels et al. 2008). These inverse associations suggest that
decreased circulating testosterone level diminishes prostate cancer risk, as seen among
the HCV-infected individuals.
In a study investigating cancer risks among elderly people with end-stage renal disease
(ESRD, Shebl et al. 2012), the authors discovered that ESRD was associated with
reduced risk for prostate cancer (OR=0.42, 95%CI: 0.35-0.50) using the same SEERMedicare dataset. Shebl (2012) postulated that patients with ESRD in general have less
life expectancy, and consequently are less likely to receive PSA screening. The authors
attributed the observed lower risk to a low prevalence of PSA screening or decreased
sensitivity of the PSA test among patients with ESRD, rather than biological modulation
by ESDR.
However, the current analysis of the association between HCV infection and prostate
cancer risk yielded a different explanation. In the current study, 73.4% HCV-infected
subjects received PSA test 0-0.99 year prior to their index date, compared to
approximately 60% among the uninfected subjects. Since the prevalence of PSA
screening among HCV-infected subjects was substantially higher than the prevalence in
HCV-uninfected subjects, HCV-infected subjects should be more likely to be diagnosed
with prostate cancer. However, we actually observed a significantly reduced risk of
prostate cancer for patients with prior HCV infection (OR 0.76, 95%CI: 0.63-0.93),
indicating that this association would be even stronger without the attenuation effect from
screening. Thus, it is very likely that the decreased prostate cancer risk after HCV
infection is mediated by a biological substance-mediated mechanism and is not an artifact
caused by screening.
Interestingly, HCV infection was found to be associated with reduced prostate cancer risk
within each cancer stage category (localized, regional, distant, and unstaged) comparing
to the controls, and the strongest protective effect was observed for the most advanced
stage of prostate cancer. In addition, among prostate cancer cases, a history of HCV
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infection was associated with significantly decreased risk of distant cancer compared
with localized cancer (OR 0.64, 95% CI: 0.42-0.99), suggesting that prostate cancer
patients with HCV infection were more likely to have non-advanced cancer than
advanced cancer. However, such findings may have been due to residual confounding by
PSA screening. First, 68.0% of cases received a PSA test 0-0.99 years prior to their index
dates, compared to 35.5% of the controls; secondly, among the cases, 83.0% of HCVinfected subjects received a PSA test versus 67.9% of the HCV un-infected subjects.
Since PSA testing tends to diagnose asymptomatic cancers at an early stage, it is possible
that more non-advanced cancers were diagnosed due to the higher prevalence of PSA
screening among cases, and particularly, among HCV-infected cases. Thus, the HCVinfected cases may have been more likely to be diagnosed with non-advanced cancers,
but they may not truly enjoy a biological protective effect against advanced cancer.
The credibility of these findings is supported by various features of our study. The large
sample size of the study provided substantial statistical power to detect the association
between HCV infection and prostate cancer risk, and it enabled us to obtain a precise OR
estimate. We included all prostate cancers cases aged 66 and older in the SEER program
diagnosed during 1993-2005 and controls of the same age and from the same geographic
areas. Thus, our study subjects were highly representative of the US elderly population.
In addition, for patients who had screening-detected cancer, they were most likely to have
received their PSA test within a short period prior to their cancer diagnosis. Thus,
adjustment for PSA test 0-0.99 years prior to the index dates in the multivariate model
addressed the potential confounding caused by screening, and ensured the validity of the
observed association between HCV infection and decreased prostate cancer risk.
Some limitations of our study are worth noting. First, we used Medicare claims data to
ascertain HCV infection status, which is likely to underestimate the prevalence of HCV
infection, considering that people often live asymptomatically for decades after their
initial acute infection with HCV; in addition, it is possible that some of the identified
subjects with ICD-9 code for HCV infection are actually false positives, which would
decrease the specificity of our method of identifying exposure status. These situations
would jeopardize the validity of our point estimate if the prostate cancer cases and
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controls exhibited systematically different likelihoods of detection of their HCV
infection. Secondly, controls were frequency matched to the age, race and calendar year
of selection distribution of cancer cases of all type; selection of prostate cancer cases and
all male controls for the current study broke this matching. However, the prostate cancer
cases and controls were very balanced on age and race, and reasonably balanced on
calendar-period of selection (Table 1); furthermore we adjusted for these variables in the
multivariate model to adjust for any residual confounding. Thirdly, some of the identified
PSA test may be performed after prostate cancer was suspected due to signs or
symptoms, in which case, the PSA tests were not used as screening tests but diagnostic
tests.

CONCLUSIONS
In conclusion, we conducted the first population-based case-control study to investigate
the association between HCV infection and prostate cancer risk with a large sample size.
We found that HCV infection was significantly associated with decreased risk of
developing prostate cancer. This association is grounded by a plausible biological
mechanism involving decreased concentration of circulating testosterone. More in-depth
research is needed to verify the underlying mechanism for the inverse association
between HCV infection and prostate cancer. Further exploration of the association
between HCV infection and stage at diagnosis of prostate cancer, as well as the role of
PSA screening in this association, will also help elucidate the biological basis for our
novel finding.
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